€106.7 B

SAN.PA Mkt cap, 07-May-2021
Sanofi Gross profit (FY, 2020)-13.1 B
Sanofi Gross profit margin (FY, 2020), %1412.9%
Sanofi Net income (FY, 2020)12.4 B
Sanofi EBIT (FY, 2020)14.1 B
Sanofi Cash, 31-Dec-202013.9 B
Sanofi EV112.5 B

Sanofi Revenue

Sanofi revenue was (€926 m) in FY, 2020

Embed Graph

Sanofi Revenue Breakdown

Embed Graph

Sanofi revenue breakdown by business segment: 15.9% from Vaccines, 71.2% from Pharmaceuticals and 13.0% from Consumer Healthcare

Sanofi revenue breakdown by geographic segment: 30.2% from Emerging Markets, 24.5% from Europe, 35.3% from United States and 10.0% from Rest of the World

Sanofi Income Statement

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

35.1b34.5b36.1b(926.0m)

Revenue growth, %

(2%)5%

Cost of goods sold

11.6b11.4b12.0b12.2b

Gross profit

24.6b24.2b25.7b(13.1b)

Gross profit Margin, %

70%70%71%1413%

R&D expense

5.5b5.9b6.0b

General and administrative expense

10.1b9.9b9.9b

Operating expense total

18.8b19.6b22.5b11.1b

Depreciation and amortization

1.9b2.2b2.1b

EBIT

5.8b4.7b3.1b14.1b

EBIT margin, %

17%14%9%(1527%)

Interest expense

420.0m435.0m444.0m

Interest income

147.0m164.0m141.0m

Pre tax profit

5.5b4.4b2.8b

Income tax expense

1.7b481.0m139.0m1.8b

Net Income

8.6b4.4b2.8b12.4b

EPS

6.73.42.2

Half Year

EURH1, 2018H1, 2019H1, 2020

Revenue

16.1b17.0b17.2b

Cost of goods sold

5.3b5.4b5.5b

Gross profit

11.3b12.3b12.2b

Gross profit Margin, %

71%72%71%

R&D expense

2.8b3.0b2.7b

General and administrative expense

4.8b4.8b4.6b

Operating expense total

9.2b11.2b2.1b

Depreciation and amortization

999.0m1.1b883.0m

EBIT

2.2b1.1b10.1b

EBIT margin, %

13%7%59%

Interest expense

202.0m244.0m198.0m

Interest income

97.0m94.0m31.0m

Pre tax profit

2.1b962.0m9.9b

Income tax expense

297.0m13.0m994.0m

Net Income

1.8b1.1b9.3b

EPS

1.40.87.4

Sanofi Balance Sheet

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

10.3b6.9b9.4b13.9b

Accounts Receivable

7.2b7.3b7.9b7.5b

Prepaid Expenses

336.0m469.0m493.0m

Inventories

6.8b7.5b8.0b8.4b

Current Assets

26.4b24.6b28.6b

PP&E

9.6b9.7b9.7b9.4b

Goodwill

40.3b44.2b44.5b44.4b

Total Assets

99.8b111.4b112.7b114.5b

Accounts Payable

4.6b5.0b5.3b

Short-term debt

1.3b2.6b4.8b

Current Liabilities

15.5b17.4b20.4b

Long-term debt

14.3b22.0b21.1b19.7b

Non-Current Liabilities

26.1b35.0b33.2b32.1b

Total Debt

15.6b24.6b25.9b19.7b

Common Stock

2.5b2.5b2.5b

Additional Paid-in Capital

58.0m(267.0m)147.0m

Total Equity

58.3b59.0b59.1b63.1b

Debt to Equity Ratio

0.3 x0.4 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

1.7 x1.9 x1.9 x1.8 x

Half Year

EURH1, 2018H1, 2019H1, 2020

Cash

7.5b6.7b16.0b

Accounts Receivable

6.6b7.2b7.2b

Inventories

7.4b8.4b8.9b

Current Assets

23.9b25.3b34.8b

PP&E

9.5b9.6b9.4b

Goodwill

44.8b44.4b45.3b

Total Assets

112.8b110.5b115.8b

Accounts Payable

4.6b5.1b4.9b

Short-term debt

6.2b4.7b3.6b

Current Liabilities

19.6b19.2b18.8b

Long-term debt

22.8b22.0b21.4b

Non-Current Liabilities

36.5b34.8b33.5b

Total Debt

28.9b26.7b24.9b

Common Stock

2.5b2.5b2.5b

Additional Paid-in Capital

51.0b49.9b181.0m

Total Equity

56.4b56.5b63.5b

Debt to Equity Ratio

0.5 x0.5 x0.4 x

Debt to Assets Ratio

0.3 x0.2 x0.2 x

Financial Leverage

2 x2 x1.8 x

Sanofi Cash Flow

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Depreciation and Amortization

3.7b4.3b7.5b

Accounts Receivable

(529.0m)(35.0m)(462.0m)

Inventories

(145.0m)(701.0m)(547.0m)

Accounts Payable

577.0m270.0m169.0m

Cash From Operating Activities

7.4b5.5b7.7b7.4b

Purchases of PP&E

(2.0b)(2.0b)(1.8b)

Cash From Investing Activities

639.0m(12.9b)(1.1b)3.6b

Short-term Borrowings

30.0m(168.0m)(154.0m)

Long-term Borrowings

(2.4b)(787.0m)(2.3b)

Dividends Paid

(3.7b)(3.8b)(3.8b)

Cash From Financing Activities

(7.9b)3.9b(4.2b)(6.5b)

Net Change in Cash

42.0m(3.4b)2.5b

Interest Paid

347.0m(412.0m)379.0m

Income Taxes Paid

1.7b(2.1b)1.7b

Half Year

EURH1, 2018H1, 2019H1, 2020

Depreciation and Amortization

1.8b3.8b2.0b

Accounts Receivable

571.0m90.0m516.0m

Inventories

(627.0m)(934.0m)(1.0b)

Accounts Payable

(219.0m)(49.0m)(325.0m)

Cash From Operating Activities

1.8b3.2b3.9b

Purchases of PP&E

(823.0m)(841.0m)(682.0m)

Cash From Investing Activities

(13.1b)(165.0m)(8.1b)

Short-term Borrowings

3.4b(13.0m)923.0m

Long-term Borrowings

(25.0m)(1.4b)(4.1b)

Dividends Paid

(3.8b)(3.8b)(3.9b)

Cash From Financing Activities

8.5b(3.2b)(5.4b)

Net Change in Cash

(2.8b)(183.0m)6.5b

Interest Paid

144.0m202.0m174.0m

Income Taxes Paid

1.1b724.0m383.0m

Sanofi Ratios

EURFY, 2017

EV/EBIT

18.5 x

EV/CFO

14.6 x

Revenue/Employee

329.0k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x

P/E Ratio

12.3

Sanofi Operating Metrics

FY, 2018FY, 2019FY, 2020

Production Sites

7573

R&D Centers

2020

Suppliers

86 k68 k

Projects in R&D Pipeline

8191

Phase I Trials Products (Oncology)

61012

Phase II Trials Products (Oncology)

566

Phase III/Filed Trials Products (Oncology)

786

Phase I Trials Products (Immunology and Inflamation)

133

Phase II Trials Products (Immunology and Inflamation)

881

Phase III/Filed Trials Products (Immunology and Inflamation)

693

Phase I Trials Products (Rare Diseases)

1

Phase II Trials Products (Rare Diseases)

444

Phase III/Filed Trials Products (Rare Diseases)

333

Phase I Trials Products (Vaccines)

342

Phase II Trials Products (Vaccines)

414

Phase III Trials Products (Vaccines)

453

Filed Trials Products (Vaccines)

21

Phase I Trials Products (Rare Blood Disorders)

444

Phase III/Filed Trials Products (Rare Blood Disorders)

244

Phase I Trials Products (Multiple Sclerosis Neurology)

222

Phase II Trials Products (Multiple Sclerosis Neurology)

231

Phase III/Filed Trials Products (Multiple Sclerosis Neurology)

223

Phase III/Filed Trials Products (Diabetes and Cardiovascular)

74

Sanofi Sustainability Metrics

 FY, 2019

Water Withdrawn (Surface Water)

8.9 m cubic meters

Water Withdrawn (Other Suppliers)

200 k cubic meters

Water Withdrawn (Municipal)

7.5 m cubic meters

Water Withdrawn (Ground Water)

18 m cubic meters

Water Withdrawn

34.6 m cubic meters

Wastewater Discharged

2.07 k tonnes

Total Solvents Used

184.91 k tonnes

Total Occupational Injury Frequency Rate (Sanofi Employees)

1.7

Total Occupational Injury Frequency Rate (Any Employees)

2.1

Solvents Recycled, percent

62%

Number of Occupational Diseases

28

Number of Fatalities

2

Nonhazardous Waste Generated

139.49 k tonnes

Nonhazardous Waste (Recycled)

90.87 k tonnes

Nonhazardous Waste (Landfilled)

18.04 k tonnes

Nonhazardous Waste (Incinerated without Thermal Recovery )

7.4 k tonnes

Nonhazardous Waste (Incinerated with Thermal Recovery )

23.18 k tonnes

Lost Time Injury Frequency Rate (Sanofi Employees)

1.3

Lost Time Injury Frequency Rate (Any Employees)

1.5

Hazardous Waste Generated

128.34 k tonnes

Hazardous Waste (Recycled)

28.82 k tonnes

Hazardous Waste (Landfilled)

2.66 k tonnes

Hazardous Waste (Incinerated without Thermal Recovery )

38.58 k tonnes

Hazardous Waste (Incinerated with Thermal Recovery )

58.28 k tonnes

Greenhouse Gas Emissions (Scope 3, Waste Generated in Operations)

372.44 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Use of Sold Products)

55.86 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Upstream Transportation and Distribution)

216.48 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Upstream Activities)

5.73 m metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Purchased Goods and Services)

3.82 m metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Processing of Sold Products)

112.52 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Fuel and Energy-Related Activities)

358.68 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, End-of-Life Treatment of Sold Products)

222.7 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Employee Commuting)

150.77 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Downstream Transportation and Distribution)

874 metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Downstream Activities)

391.95 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Capital Goods)

652.79 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Business Travel)

154.99 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3)

6.12 m metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 2)

370.51 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1, Sales Feet Fuels)

99.31 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1, Natural Gas, Fuels, Refrigerant Leaks)

460.11 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

559.42 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1 and Scope 2)

929.93 k metric tons of carbon dioxide equivalent

Energy Consumption (Renewables)

186.93 k MWh

Energy Consumption (Other)

471.02 k MWh

Energy Consumption (Natural Gas)

2.13 m MWh

Energy Consumption (Electricity)

1.43 m MWh

Energy Consumption

4.22 m MWh

Air Emissions (Volatile Organic Compound)

3.09 k tonnes

Air Emissions (Sulfur Oxide)

97 tonnes

Air Emissions (Nitrogen Oxides)

442 tonnes

Sanofi Human Capital

Gender

FY, 2019FY, 2018
Female, percent46.2%46.2%
Male, percent53.8%53.8%

Sanofi Employee Rating

3.39 votes
Culture & Values
4.1
Work/Life Balance
3.8
Senior Management
3.3
Salary & Benefits
2.7
Career Opportunities
3
Source